Vicore advances on new chemical entity from VP03 program
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
The facility will manufacture its Herceptin biosimilar, Tuznue
9T Labs provides a cost-competitive solution for manufacturing that will allow structural CFRP parts to replace metals at a much faster rate in demanding applications in many sectors such as aerospace, automotive and healthcare
Subscribe To Our Newsletter & Stay Updated